| Literature DB >> 29862031 |
Erik H F M van der Heijden1, Piero Candoli2, Igor Vasilev3, Alessandro Messi2, Javier Pérez Pallarés4, Piotr Yablonskii3, Anna van der Vorm1,5, Olga C J Schuurbiers1, Wouter Hoefsloot1.
Abstract
INTRODUCTION: Patients with lung cancer may present with additional lesions in the central airways. Earlier studies have shown a relationship between vessel diameter, pattern and grade of malignancy. High-definition (HD+) bronchoscopy with image enhancement techniques (i-scan) detected more vascular abnormalities but correlation with pathology has not yet been established.Entities:
Keywords: bronchoscopy; histology/cytology; imaging/ct MRI etc; lung cancer; non-small cell lung cancer
Year: 2018 PMID: 29862031 PMCID: PMC5976136 DOI: 10.1136/bmjresp-2018-000295
Source DB: PubMed Journal: BMJ Open Respir Res ISSN: 2052-4439
Figure 1Sample figures of typical bronchoscopy findings illustrating the effect of i-scan image enhancement technique and differences in vascular patterns. (A–C) A centrally located squamous cell carcinoma in the right main stem bronchus with high-definition bronchoscopy (A), surface enhancement (i-scan1, B) and the combination of surface and tone enhancement (i-scan 2, C). (D–F) Different vascular patterns are illustrated. (D) Tortuous or spiral vessels, (E) dotted vessels and (F) abrupt ending vessels.
Figure 2Consort diagram i-scan multicentre trial NCT02285426 (clinicaltrials.gov). *The non-lung cancer diagnosis found metastasis of melanoma, metastasis of liposarcoma, malignant mesothelioma, pulmonary lymphoma localisation and a papillary adenoma. The most frequently found reason for exclusion in the screened patients was an alternative explanation found by CT or positron emission tomography scan for the presumed lung cancer suspected on chest X-ray on referral and prior radiotherapy treatment involving the central airways.
baseline characteristics i-scan multicentre study
| Baseline characteristics, n=107 | N | % |
| Age (median; range 23–85 years) | 67 | |
| Gender (female:male) | 32:75 | 30:70 |
| Performance status | ||
| ECOG 0 | 43 | 40 |
| ECOG 1 | 50 | 47 |
| ECOG 2 | 12 | 11 |
| ECOG 3 | 1 | 1 |
| Preprocedure evaluation (available imaging prior to bronchoscopy | ||
| CT thorax | 92% | |
| PET-CT | 76% | |
| Localisation tumour target lesion | ||
| LUL | 30 | 28 |
| LLL | 9 | 8 |
| RUL | 45 | 42 |
| ML | 10 | 9 |
| RLL | 18 | 17 |
| Clinical TNM stage (v7) prior to bronchoscopy | ||
| Ia | 16 | 15 |
| Ib | 8 | 8 |
| IIa | 10 | 9 |
| IIb | 3 | 3 |
| IIIa | 40 | 37 |
| IIIb | 7 | 7 |
| IV | 23 | 22 |
|
| ||
| Sedation for bronchoscopy | ||
| None | 15 | 14 |
| Midazolam (mean dose: 4.72±0.4 mg, range 1.3–9.0 mg) | 25 | 23 |
| Propofol | 39 | 36 |
| General anaesthesia | 28 | 26 |
| Study procedure time (min) | 11±0.8 | |
| Use of fluoroscopy | 29 | 27 |
| Complications | 10 | 9 |
| Haemorrhage needing topical agents | 5 | 4.7 |
| Severe haemorrhage | 0 | 0 |
| Dyspnoea | 1 | 0.9 |
ECOG, Eastern Cooperative Oncology Group; LLL, left lower lobe; LUL, left upper lobe; ML, middle lobe; PET, positron emission tomography; RLL, right lower lobe; RUL, right upper lobe; TNM, tumour, node, metastases.
Bronchoscopy pathology outcome
| Bronchoscopy pathology outcome | Target tumour | Secondary lesions | Control biopsies | |||
| N | % | N | % | N | % | |
| Pathology outcome | 107 | 51 | 53 | |||
| Normal | – | – | 15 | 29 | 33 | 62 |
| Inflammation | – | – | 17 | 33 | 19 | 36 |
| Hyperplasia | – | – | 2 | 4 | – | – |
| Squamous metaplasia | – | – | 3 | 6 | 1 | 2 |
| Mild dysplasia | – | – | 3 | 6 | – | – |
| Moderate dysplasia | – | – | 0 | 0 | – | – |
| Severe dysplasia | – | – | 1 | 2 | – | – |
| CIS | – | – | 1 | 2 | – | – |
| Invasive carcinoma | 107 | 100 | 9 | 18 | – | – |
| NSCLC—SqCC | 43 | 40 | 1 | 2 | – | – |
| NSCLC—AC | 39 | 36 | 7 | 14 | – | – |
| NSCLC—LCNOS | 5 | 5 | – | – | – | – |
| LCNEC | 2 | 2 | – | – | – | – |
| SCLC | 11 | 10 | – | – | – | – |
| Typical carcinoid | 6 | 6 | – | – | – | – |
| Mucoepidermoid cell carcinoma | 1 | 1 | – | – | – | – |
| LGSDC* | – | – | 1 | 2 | – | – |
*Published as case report.18
AC, adenocarcinoma; CIS, carcinoma in situ; LCNEC, large cell neuroendocrine carcinoma; LCNOS, large cell not otherwise classified; LGSDC, low-grade salivary duct cell carcinoma; NSCLC, non-small cell lung cancer, SCLC, small cell lung cancer; SqCC, squamous cell carcinoma.
High-definition bronchoscopy findings 5 11–13
| Bronchoscopy outcome | Target tumour | Secondary lesions | ||
| N | % | N | % | |
|
| 106 | 51 | ||
| Normal | 40 | 37 | 4 | 8 |
| Abnormal | 3 | 3 | 35 | 69 |
| Suspicious | 7 | 7 | 9 | 18 |
| Tumour | 56 | 52 | 3 | 6 |
|
| 48 | 50 | ||
| Spiral/tortuous vessel pattern | 10 | 21 | 38 | 76 |
| Dotted vessels | 11 | 23 | 9 | 18 |
| Abrupt ending vessels | 27 | 56 | 3 | 6 |
Definitions for visual grade and vascular pattern described in ‘Methods’ section and in refs. 5 11–13
Correlation between vascular pattern and pathology outcome of the target tumour lesions (n=48 lesions with vascular patterns classified)
| Target tumour vascular lesions (n=48) | Vascular pattern | ||
| Pathology outcome | Spiral/ | Dotted | Abrupt ending |
| Adenocarcinoma | 5 | 4 | 4 |
| Squamous cell carcinoma | 3 | 4 | 14 |
| LCNOS | 1 | 1 | 1 |
| SCLC | 1 | 2 | 4 |
| Typical carcinoid | 0 | 0 | 4 |
Fisher’s exact testing is not significant: p = 0.339. No vascular pattern classification available of the mucoepidermoid cell carcinoma (n = 1) and LCNEC’s (n = 2).
LCNEC, large cell neuroendocrine carcinoma; LCNOS, large cell not otherwise classified; SCLC, small cell lung cancer.
Correlation between vascular pattern and pathology outcome of second, anatomically separated lesions detected (n=48 classified lesions)
| Secondary vascular lesions (n=51) | Vascular pattern | ||
| Pathology outcome | Spiral/ | Dotted | Abrupt ending |
| Normal – Moderate dysplasia | 36 | 4 | 0 |
| Severe dysplasia – Invasive carcinoma | 3 | 5 | 3 |
Fisher’s exact testing shows a significant relation; p = 0.000.
Cohen’s kappa interobserver agreement (±SE)
| HD+ | SE (i-scan1) | SE+TE (i-scan2) | ||||
| Kappa | P values | Kappa | P values | Kappa | P values | |
| Visual grade | 0.616±0.073 | 0.0000 | 0,631±0.078 | 0.0000 | 0.683±0.094 | 0.0000 |
| Vascular pattern | 0.261±0.084 | 0.0010 | 0.228±0.101 | 0.0119 | 0.303±0.071 | 0.0000 |
HD+, high-definition bronchoscopy; SE, surface enhancement; TE, tone enhancement.
Wilcoxon signed-rank test i-scan1 and i-scan2 compared with high-definition (HD+) bronchoscopy and blinded randomised evaluation compared with unblinded primary evaluation in randomised order
| SE (i-scan1) vs HD+ | SE+TE (i-scan2) vs HD+ | Blinded vs unblinded | ||||
| Z | P values | Z | P values | Z | P values | |
| Visual grade | 1.092 | 0.2747 | −0.031 | 0.9755 | −1.859 | 0.0631 |
| Vascular pattern | 2.105 | 0.0353 | −2.807 | 0.0050 | −1.443 | 0.1489 |
SE, surface enhancement; TE, tone enhancement.
Detailed patient characteristics and bronchoscopy findings of patients with clinically relevant second lesions (severe dysplasia or worse at second, anatomical separate location)
| Patient code | Age | Sex | Imaging-based cTNM | Target tumour location/VG/VP | Pathology target tumour | Second lesion location/VG/VP | Pathology outcome second lesion | Third lesion location/VG/VP | Pathology outcome third lesion | Initial treatment target tumour | Additional or altered treatment; effect on cTNM |
| Nij10 | 67 | m | cT2aN1M0 | RB9/t/ae | SqCC | LC1/s/d | LGSDC | – | – | Lobectomy RLL: pT2a pN1 cM0 SqCC | Local endobronchial resection+follow-up |
| Nij12 | 63 | m | cT2bN2M1b | RB2/t/ s | AC | RC1/a/ s | AC | – | – | Chemotherapy | None (proven distant bone metastasis); upstaging to cT3 |
| Nij13 | 58 | m | cT2aN1M1b | LB1/t/ s | AC | LB4/a/ s | AC | – | – | Chemotherapy | None (proven distant bone metastasis); upstaging to cT3 |
| Nij17 | 72 | m | cT3N0M0 | RIB/t/ae | SqCC | LC2/a/d | Severe dysplasia | – | – | Radiotherapy right-sided tumour | Local treatment LC2+follow-up |
| Nij28 | 54 | f | cT3N2M1b | RB8/n/x | AC | RC1/t/ae | AC | LMB/s/d | AC | Chemotherapy | None (LAG metastasis proven with EUSb); upstaging to cT4 and cM1a |
| Nij54 | 73 | m | cT3N2M1a | RB8/t/d | AC | RC1/s/ae | AC | – | – | Chemotherapy | None (pleural metastases proven); upstaging to cT4 |
| Nij79 | 61 | m | cT4N3M1b | RB2/t/ d | AC | LMB/t/ d | AC | Tr/t/ d | AC | Chemotherapy | None (lung, brain and bone metastases); upstaging cT4 (central) and cM1a (contralateral)>M1b proof no longer required |
| Rav6 | 57 | m | cT2aN2M1a | LB2/t/a | SqCC | LMB/a/ s | CIS | – | – | Chemotherapy | None (pleural metastasis proven) |
| Rav7 | 66 | m | cT3N2M0 | RB1/t/ae | SqCC | RIB/a/ae | SqCC | – | – | Chemoradiotherapy | None (N2 disease proven); upstaging to cT4 |
Imaging-based cTNM indicates stage based on imaging available before the bronchoscopy (TNM V.7).
n = 11 lesions in n = 9 patients, that is, 21,6% of a total of 51 secondary lesions detected in 8.45% of the total of 107 patient s with lung cancer.
Nij10: case report published, see ref.18
Visual grade (VG): a, abnormal; n, normal; s, suspicious; t, tumour.
Vascular pattern (VP): ae, abrupt ending; d, dotted; s, spiral/tortuous; x, missing.
AC, adenocarcinoma; LB4, left bronchial segment 4; LC1, left carina 1; LC2, left carina 2; LCNEC, large cell neuroendocrine carcinoma; LCNOS, large cell not otherwise classified; LGSDC, low-grade salivary duct cell carcinoma; LMB, left main stem bronchus; NSCLC, non-small cell lung cancer; RC1, right carina 1; RIB, right bronchus intermedius; RMB, right main stem bronchus; SCLC, small cell lung cancer; SqCC, squamous cell carcinoma; TNM, tumour, node, metastases; Tr, trachea.